GRP
AIMT

Global Retirement Partners’s Aimmune Therapeutics AIMT Stock Holding History

Global Retirement Partners’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-623
Closed -$10K – 1762
2020
Q2 		$10K Buy
+623
New +$10.6K ﹤0.01% 1129

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Global Retirement Partners's AIMT Position: Q3 2020 in Review

Global Retirement Partners sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 623 shares — an estimated $10K sold.

Global Retirement Partners first reported a position in AIMT in Q2 2020 and held it in 1 quarter. The position peaked at $10K in Q2 2020. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Global Retirement Partners reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Global Retirement Partners sold 623 Aimmune Therapeutics shares in Q3 2020, an estimated $10K.
  • Global Retirement Partners first reported a position in Aimmune Therapeutics in Q2 2020 and held it in 1 quarter.
  • Global Retirement Partners's Aimmune Therapeutics position peaked at $10K in Q2 2020.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Global Retirement Partners's 13F filing for Q3 2020, filed 9 Oct 2020.